AU2004288641B2 - Use of selective opiate receptor modulators in the treatment of neuropathy - Google Patents

Use of selective opiate receptor modulators in the treatment of neuropathy Download PDF

Info

Publication number
AU2004288641B2
AU2004288641B2 AU2004288641A AU2004288641A AU2004288641B2 AU 2004288641 B2 AU2004288641 B2 AU 2004288641B2 AU 2004288641 A AU2004288641 A AU 2004288641A AU 2004288641 A AU2004288641 A AU 2004288641A AU 2004288641 B2 AU2004288641 B2 AU 2004288641B2
Authority
AU
Australia
Prior art keywords
compounds
neuropathy
diabetic
phenyl
hydroxypyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004288641A
Other languages
English (en)
Other versions
AU2004288641A1 (en
Inventor
Gerd Bartoszyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tioga Pharmaceuticals Inc
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Publication of AU2004288641A1 publication Critical patent/AU2004288641A1/en
Application granted granted Critical
Publication of AU2004288641B2 publication Critical patent/AU2004288641B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004288641A 2003-10-30 2004-10-14 Use of selective opiate receptor modulators in the treatment of neuropathy Ceased AU2004288641B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03024781 2003-10-30
EP03024781.1 2003-10-30
PCT/EP2004/011548 WO2005046687A1 (en) 2003-10-30 2004-10-14 Use of selective opiate receptor modulators in the treatment of neuropathy

Publications (2)

Publication Number Publication Date
AU2004288641A1 AU2004288641A1 (en) 2005-05-26
AU2004288641B2 true AU2004288641B2 (en) 2010-08-12

Family

ID=34585870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004288641A Ceased AU2004288641B2 (en) 2003-10-30 2004-10-14 Use of selective opiate receptor modulators in the treatment of neuropathy

Country Status (7)

Country Link
US (1) US20080090859A1 (enExample)
EP (1) EP1680115A1 (enExample)
JP (2) JP2007509865A (enExample)
AR (1) AR046219A1 (enExample)
AU (1) AU2004288641B2 (enExample)
CA (1) CA2544245A1 (enExample)
WO (1) WO2005046687A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
CN114678927B (zh) * 2022-03-22 2026-03-31 浙江地芯引力科技有限公司 一种充电线材充电控制方法、充电线材

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093852A2 (en) * 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
WO2002080905A1 (de) * 2001-04-05 2002-10-17 Merck Patent Gmbh Kappa-opiatagonisten für die behandlung von erkrankungen der blase
US20030199424A1 (en) * 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2550077A (en) * 1976-06-14 1978-11-30 Merck Patent Gmbh Penicillins and cephalosporins
DE3738844A1 (de) * 1987-11-16 1989-05-24 Merck Patent Gmbh Analgetikum
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4407047A1 (de) * 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
BR0015294A (pt) * 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US20050176746A1 (en) * 2002-05-17 2005-08-11 Frank Weber Use of compounds that are effective as selective opiate receptor modulators
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093852A2 (en) * 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
WO2002080905A1 (de) * 2001-04-05 2002-10-17 Merck Patent Gmbh Kappa-opiatagonisten für die behandlung von erkrankungen der blase
US20030199424A1 (en) * 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Walker, J et al. Pain Vol 83 1999 Pages 506-516 *
Watson C P N et al. Neurology, Lippincott Williams & Wilkins, US, Vol 50 No 6 June 1998 *

Also Published As

Publication number Publication date
CA2544245A1 (en) 2005-05-26
AU2004288641A1 (en) 2005-05-26
WO2005046687A1 (en) 2005-05-26
AR046219A1 (es) 2005-11-30
US20080090859A1 (en) 2008-04-17
JP2007509865A (ja) 2007-04-19
EP1680115A1 (en) 2006-07-19
JP2013035873A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
US10857204B2 (en) Method for administering omega-conopeptide
US11529337B2 (en) Method of treating pain
KR100758609B1 (ko) 트라마돌 화합물 및 항경련 약물을 포함하는 조성물
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
RU2135179C1 (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
CN105367485B (zh) 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
US20120077818A1 (en) Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
US20100197704A1 (en) Pharmaceutical compositions and method for treating acute mania
US20190381017A1 (en) Compositions Comprising Serdexmethylphenidate Conjugates And Methods Of Use Thereof
EP0610021A1 (en) Pharmaceutical agents for treatment of urinary incontinence
JP2013035873A (ja) 神経障害の治療における選択的オピエート受容体調節物質の使用
KR100195651B1 (ko) 신경 손상 및 발작의 치료를 위한 nk-1 수용체 길항물질
JP7653428B2 (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
MXPA01001461A (es) Metabolitos de difenhidramina no sedantes.
RU2646475C2 (ru) Лечение диабета I и II типа
PT95698B (pt) Processo para a preparacao de composicoes farmaceuticas contendo aril-alquilamidas utilizadas no tratamento de doencas neurodegenarativas
JP2007509865A5 (enExample)
HK40077785A (en) D-amphetamine compounds, compositions, and processes for making and using the same
HK1136984B (en) Carbamoyl-cyclohexanes for treating acute mania

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired